SQZ Biotechnologies (OTCMKTS:SQZB – Get Free Report) is expected to be issuing its resultson Thursday, November 12th. Analysts expect SQZ Biotechnologies to post earnings of ($0.5825) per share and revenue of $4.66 million for the quarter.
SQZ Biotechnologies Price Performance
Shares of SQZB stock opened at $0.02 on Tuesday. SQZ Biotechnologies has a 12-month low of $0.01 and a 12-month high of $0.05. The business’s fifty day simple moving average is $0.02 and its 200-day simple moving average is $0.02.
SQZ Biotechnologies Company Profile
SQZ Biotechnologies Co was a biotechnology company that developed cell therapies using its proprietary Cell Squeeze technology. The platform was designed to deliver biological materials, including proteins, nucleic acids and other therapeutic payloads, directly into cells while preserving cell viability and function.
The company focused primarily on oncology and immunology applications. Its research programs included engineered immune-cell therapies intended to stimulate anti-tumor responses, including programs involving antigen-presenting cells and peripheral blood mononuclear cells.
Read More
- Five stocks we like better than SQZ Biotechnologies
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
